Zentalis Pharmaceuticals Announces Promising Initial Data Presented in a Late-Breaking Session at AACR on ZN-c3, its WEE1 Inhibitor, in Patients with Advanced Solid Tumors
Go back to Zentalis Pharmaceuticals Announces Promising Initial Data Presented in a Late-Breaking Session at AACR on ZN-c3, its WEE1 Inhibitor, in Patients with Advanced Solid Tumors| (NASDAQ: ZNTL) | Delayed: 11.77 -0.8 (6.36%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $12.57 | 52 Week High | $ | |||
| Open | $12.50 | 52 Week Low | $ | |||
| Day High | $12.59 | P/E | N/A | |||
| Day Low | $11.63 | EPS | $ | |||
| Volume | 854,473 | |||||
